MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Stan Smith Acquires 19,230 Shares

Key Points

• MAIA Biotechnology's Director Stan Smith acquired 19,230 shares at an average price of $1.30 per share, increasing his total holdings to 1,324,289 shares valued at approximately $1.72 million.
• Following the acquisition, MAIA's stock traded up 8.4% to $1.80, with significant trading volume of 2,396,587 shares compared to its average of 355,309 shares.
• Institutional investors now own 5.65% of the company, with recent investments including Jane Street Group LLC and Centric Wealth Management, which increased its holdings by 740.2%.

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - ) Director Stan Smith purchased 19,230 shares of the stock in a transaction that occurred on Wednesday, October 1st. The shares were purchased at an average cost of $1.30 per share, for a total transaction of $24,999.00. Following the completion of the acquisition, the director directly owned 1,324,289 shares of the company's stock, valued at $1,721,575.70. This represents a 1.47% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

MAIA Biotechnology Trading Up 8.4%

MAIA traded up $0.14 on Thursday, reaching $1.80. The stock had a trading volume of 2,396,587 shares, compared to its average volume of 355,309. The business's 50-day moving average price is $1.58 and its two-hundred day moving average price is $1.70. The company has a market cap of $59.38 million, a P/E ratio of -3.16 and a beta of 0.01. MAIA Biotechnology, Inc. has a 12-month low of $1.40 and a 12-month high of $3.48.

Hedge Funds Weigh In On MAIA Biotechnology

A number of large investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in MAIA Biotechnology in the fourth quarter valued at approximately $77,000. Centerpoint Advisory Group purchased a new position in shares of MAIA Biotechnology during the 2nd quarter valued at approximately $28,000. Geode Capital Management LLC grew its stake in MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock valued at $400,000 after acquiring an additional 7,746 shares during the period. Centric Wealth Management increased its holdings in MAIA Biotechnology by 740.2% in the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company's stock worth $1,032,000 after acquiring an additional 505,150 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in MAIA Biotechnology during the second quarter worth $29,000. Institutional investors and hedge funds own 5.65% of the company's stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.